Immunologix bolsters its scientific expertise with two new hires to build on its bioanalytical biomarker programs created from the launch of its Translational Sciences division.
LabCorp participated in a $3m Series B2 financing round for Kiyatec, which is developing ex vivo 3D cell culture technology to help model and predict cancer patients’ response to drug therapies.
Increasingly concerned with the potential for cyber attacks at third-party vendors, pharma looks to gain visibility into supplier performance, says industry expert after the recent breach at Charles River.
Bioanalytical Systems acquires Smithers Avanza Toxicology Services business unit in response to a strong demand for its toxicology and drug disposition services.
Medicines Discovery Catapult launches a Virtual R&D Discovery Services platform made up of more than 20 CROs, which will help support small- to medium-sized companies deliver drug discovery projects.
LabCorp’s Covance Drug Development segment is set to acquire Envigo’s nonclinical research services business for $485m – while Envigo will purchase Covance’s research products business.
Acorn AI is designed to answer questions across all phases of drug development, making data “liquid” to help pharma make quick “go/no-go” decisions, accelerate clinical trials, and demonstrate value.
Taconic Biosciences’ new solution enables researchers to generate and maintain mice with custom microbiome profiles, alterations to which can significantly affect drug efficacy.
Charles River Laboratories has extended its ongoing collaboration with the CHDI Foundation by five-years – and is closing its San Diego, CA-based research model production facility.
